IQVIA

Global healthcare data and clinical research company, profiled here for its Vigilance safety platform for AI-assisted pharmacovigilance.

IQVIA, formed in 2016 through the merger of Quintiles and IMS Health and headquartered in Durham, North Carolina, is a global provider of healthcare data, analytics, and clinical research services. This profile focuses on its Vigilance safety platform: Vigilance Detect identifies adverse events, product quality complaints, and off-label use across unstructured sources such as call-center audio, emails, and social media in more than 50 languages, within what IQVIA describes as a GxP (CFR Part 11) validated workflow, and Vigilance Signal Detection supports safety signal management.

Headquarters: Durham, United States
Founded: 2016
Compliance: 21 CFR Part 11, GxP
Deployment options: cloud
Website: https://www.iqvia.com
LinkedIn: https://www.linkedin.com/company/iqvia

AI Use Cases

Case Processing Automation
Signal Detection & Aggregate Reporting

Vendor Scorecard

64% — Partial coverage. Coverage score — how completely Atlas documents IQVIA across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.

Compliance & Validation — Documented

GxP validated, 21 CFR Part 11

Deployment & Hosting — Documented

cloud

Pricing Transparency — Not documented by Atlas

Ask the vendor: What is your pricing model, and what drives total cost of ownership?

Implementation & Onboarding — Not documented by Atlas

Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?

Organization & Role Fit — Documented

Mid-Size Biotech, Large Pharma, Top 20 Pharma, CRO / CDMO, Pharmacovigilance, Data Management

Solution Scope — Documented

Adverse Event Detection, Natural Language Processing

Company Viability — Partially documented

Public, Founded 2016

Always ask the vendor

Not captured in Atlas data — confirm directly. Excluded from the score above.

Data Rights & IP

Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?

Model Credibility & Explainability

Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?

Clinical Trial Activity

2 registered trials where IQVIA is the lead sponsor. Source: ClinicalTrials.gov, verified 2026-07-29.

Phases: Phase 1 (1)

Top conditions studied: Cancer - Solid Tumours, COVID-19

COVID-19 Active Research Experience (CARE) (NCT04368065, completed)
Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours (NCT04025307, terminated)

Questions to Ask This Vendor

Can Vigilance Detect run standalone alongside our existing safety database?
Which of our data sources (audio, email, social, PSPs) does it cover, and in which languages?
What does the validated (GxP/Part 11) deployment and change-control process look like?
How are detection precision and recall measured and monitored on our data?